Loading clinical trials...

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes

NCT00943501•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered medication in blood over time) and pharmacodynamics (the determination of the effect over time and the duration of action) of multiple doses of liraglutide in the pediatric population (children).

Eligibility

Age

10 - 17 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•BMI greater than 85th percentile for age and gender
•Currently being treated with diet and exercise or metformin alone
•HbA1c (glycosylated haemoglobin) between 6.5 and 11.0%

Exclusion Criteria

•Any clinically significant disease other than type 2 diabetes, as judged by the trial physician
•Previous treatment with any anti-diabetic drug other than metformin (except for prior short term treatment, at the discretion of the trial physician)

Locations (20)

Novo Nordisk Investigational Site

Cypress, California, United States

Novo Nordisk Investigational Site

Los Angeles, California, United States

Novo Nordisk Investigational Site

Los Angeles, California, United States

Novo Nordisk Investigational Site

Aurora, Colorado, United States

Novo Nordisk Investigational Site

Iowa City, Iowa, United States

Novo Nordisk Investigational Site

Louisville, Kentucky, United States

Novo Nordisk Investigational Site

Kansas City, Missouri, United States

Novo Nordisk Investigational Site

Cincinnati, Ohio, United States

Novo Nordisk Investigational Site

Cleveland, Ohio, United States

Novo Nordisk Investigational Site

Toledo, Ohio, United States

Key Dates

Start Date

November 1, 2009

Primary Completion Date

September 1, 2011

Completion Date

September 1, 2011

Last Updated

January 26, 2017

Enrollment

21

ACTUAL participants

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

liraglutide

DRUG

placebo

DRUG

liraglutide

DRUG

placebo

DRUG

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions